Ready to prescribe Mounjaro?

How to Prescribe

How to Dose

Patient Start Resources

Want to connect with a local rep or request a demo pen?

Access Additional Start Resources ||| h3

https://main--ewi-mounjaro-aem-us--elilillyco.aem.page/fragments/forms/getting-patients-started

By providing my professional information, I agree that it may be used by Eli Lilly and Company ("Lilly") and its affiliates and partners or third parties, working on Lilly's behalf, for Lilly's marketing or promotional purposes. I may unsubscribe/opt-out by clicking the unsubscribe link within any email I receive or by calling 1-800-LILLYRX (1-800-545-5979). For more information about Lilly's privacy practices, please view the Privacy Statement and Consumer Health Privacy Notice.

How to Prescribe Mounjaro | prescribing

Help get patients started on Mounjaro1

Mounjaro 2.5 mg pen

Start

Provide patients with a 1-month* 2.5 mg starting dose prescription

The 2.5-mg dose is for treatment initiation and is not intended for glycemic control.

Rx pad with text that says: Mounjaro 5 milligram pen per 0.5 milliliters. Inject 5 milligrams SC once weekly. 84-day supply dispense 6 milliliters.

Prescribe

After 4 weeks on the 2.5 mg dose, provide patients with a 1-month* or 3-month 5.0-mg prescription

Icon of clipboard with illustration of shield and cross in the middle

Access

See personalized formulary access and top plans

Learn More

Icon of savings card with text that says: Pay as little as $25 for a 1-month prescription with the Mounjaro Savings Program

Activate

Help your eligible patients save on Mounjaro

For eligible, commercially insured patients with Mounjaro coverage, Governmental beneficiaries excluded, terms and conditions apply

Prior authorizations are common for the incretin therapies. Get tips for Prior Authorization Submission Process. ||| h3

Download PA Guide

*One month is defined as 28 days and 4 pens.
†Three months is defined as 84 days and up to 12 pens.
See Savings Card Terms and Conditions 2.5-mg dose NDC: 0002-1506-80; 5-mg dose NDC: 0002-1495-80

How to Dose Mounjaro | dosing

Multiple doses for customizable glycemic control1‡

START THE EXPERIENCE

Mounjaro 2.5 milligram pen once weekly

Starting dose (for 4 weeks)

Month 1

CONTINUE THE EXPERIENCE

Mounjaro 5 milligram pen once weekly

For at least 4 weeks

Month 2

IF ADDITIONAL GLYCEMIC CONTROL IS NEEDED

Mounjaro 7.5 milligram pen once weekly

For at least 4 weeks

Mounjaro 10 milligram pen once weekly

For at least 4 weeks

For at least 4 weeks

Maximum dose
The 2.5-mg dose is for treatment initiation and is not intended for glycemic control.1 The recommended dosage escalation should be followed to reduce the risk of gastrointestinal adverse reactions.
Consider patient history and monitor for tolerability and side effects.

Patient Start Resources | patient-expectation

Tips and resources for you and your staff

TODO

Completing Prior Authorization

A helpful guide on how to complete a prior authorization.

Read Guide

TODO

Getting Started Video

A video guide on initiating treatment, dosing options and what to expect with side effects

Watch Video

Resources for your patients | patient-resources

Digital Starter Kit ||| h3

Tell your patients to text MJ to 85099 to download a free kit to help them get started on Mounjaro.

The kit provides tips on starting Mounjaro, what to expect, reminder options and additional resources.

Download Patient Brochure ||| h3

The brochure provides additional tips to starting Mounjaro, what to expect, reminder options and additional resources.

Download Now

Download Savings Card ||| h3

Download a savings card for your eligible, commercially insured patients with Mounjaro coverage.*

*Governmental beneficiaries excluded, terms and conditions apply

Download Now

Discover Lilly Play

Watch videos about Mounjaro and how to help your patients get started.

Start Watching

Select Important Safety Information: ||| h6

Risk of Thyroid C-cell Tumors ||| lifestyle-purple

Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

References:

  1. Mounjaro. Prescribing Information. Lilly USA, LLC.

Mounjaro (tirzepatide) is currently only available in a pre-filled single-dose pen manufactured by Lilly. Mounjaro is not commercially available in any other form (e.g., powder for compounding). Products claiming to be compounded Mounjaro (tirzepatide) are not subject to FDA approval and may not have the same safety, quality and efficacy as FDA-approved drugs, and may expose patients to potentially serious health risks.